Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Hansa Biopharma AB (publ)    HNSA   SE0002148817

HANSA BIOPHARMA AB (PUBL)

(HNSA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Stockholm
01/12/2021 01/13/2021 01/14/2021 01/15/2021 01/18/2021 Date
193.7(c) 192.4(c) 193.9(c) 182.8(c) 190.4 Last
507 331 353 810 701 870 690 494 352 224 Volume
-2.76% -0.67% +0.78% -5.72% +4.16% Change
More quotes
Financials
Sales 2020 35,8 M 4,26 M 4,26 M
Net income 2020 -396 M -47,3 M -47,3 M
Net cash position 2020 1 385 M 165 M 165 M
P/E ratio 2020 -20,2x
Yield 2020 -
Sales 2021 99,5 M 11,9 M 11,9 M
Net income 2021 -495 M -59,1 M -59,1 M
Net cash position 2021 782 M 93,3 M 93,3 M
P/E ratio 2021 -17,1x
Yield 2021 -
Capitalization 8 468 M 1 010 M 1 010 M
EV / Sales 2020 198x
EV / Sales 2021 77,3x
Nbr of Employees 80
Free-Float 95,9%
More Financials
Company
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of... 
Sector
Biotechnology & Medical Research
Calendar
01/18 | 10:10amPräsentation
More about the company
Notations Surperformance© of Hansa Biopharma AB (publ)
Trading Rating : Investor Rating :
More Ratings
All news about HANSA BIOPHARMA AB (PUBL)
01/11HANSA BIOPHARMA : Forecasts FY20 Operating Loss to Widen
MT
01/11HANSA BIOPHARMA : provides business update incl. certain key financials ahead of..
AQ
2020HANSA BIOPHARMA :  Biopharma to present at the 39th Annual J.P. Morgan Healthcar..
AQ
2020HANSA BIOPHARMA : Nomination Committee formed
AQ
2020Hansa Biopharma interim report Jan-Sep 2020
AQ
2020HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-..
PU
2020HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-..
AQ
2020HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29,..
PU
2020HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29,..
AQ
2020HANSA BIOPHARMA : certified as a Great Place to Work
AQ
2020HANSA BIOPHARMA : provides updated guidance on its clinical programs
AQ
2020HANSA BIOPHARMA : announces participation in Fall conferences and an updated fin..
AQ
2020HANSA BIOPHARMA : ­Sale of shares in Hansa Biopharma AB (publ)
AQ
2020HANSA BIOPHARMA : The EU Commission grants conditional approval for Idefirix (im..
AQ
2020HANSA BIOPHARMA : Nexttobe announces its intention to sell shares in Hansa Bioph..
AQ
More news
News in other languages on HANSA BIOPHARMA AB (PUBL)
202010 Biotechs qui font parler d'elles
2020HANSA BIOPHARMA AB (PUBL) : Veröffentlichung des Jahresergebnisses
2020HANSA BIOPHARMA AB (PUBL) : publication des résultats annuels
2019HANSA BIOPHARMA AB (PUBL) : mauvaise nouvelle pour la biotech suédoise
More news
Chart HANSA BIOPHARMA AB (PUBL)
Duration : Period :
Hansa Biopharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HANSA BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 295,67 SEK
Last Close Price 190,40 SEK
Spread / Highest target 115%
Spread / Average Target 55,3%
Spread / Lowest Target -0,21%
EPS Revisions
Managers and Directors
NameTitle
Søren Tulstrup President & Chief Executive Officer
Ulf Arne Wiinberg Chairman
Christian Kjellman Chief Operating & Scientific Officer
Donato Spota Chief Financial Officer
Achim Kaufhold Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
HANSA BIOPHARMA AB (PUBL)-23.96%971
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-12.53%40 715
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601